• Molecular NameLevofloxacin
  • SynonymL-Ofloxacin; levofloxacin
  • Weight361.373
  • Drugbank_IDDB01137
  • ACS_NO100986-85-4
  • Show 3D model
  • LogP (experiment)-0.39
  • LogP (predicted, AB/LogP v2.0)0.0
  • pka6.0; 8.0
  • LogD (pH=7, predicted)-2.02
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.63
  • LogSw (predicted, AB/LogsW2.0)0.12
  • Sw (mg/ml) (predicted, ACD/Labs)0.62
  • No.of HBond Donors1
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds2
  • TPSA73.32
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class and is used to treat severe or life-threatening bacterial infections or bacterial infections which have failed to respond to other antibiotic classes.
  • Absorption_valueN/A
  • Absorption (description)Levofloxacin is rapidly absorbed after oral administration with maximum plasma concentrations being reached approx. 1 h after a dose. The absorption of levofloxacin is little affected by the presence of food in the gastro-intestinal tract but administration with a high fat meal may slightly prolong the time to peak concentration. It is widely distributed throughout the body, crosses the placenta and has been detected in breast milk.
  • Caco_2N/A
  • Bioavailability99.0
  • Protein binding31.0
  • Volume of distribution (VD)1.36 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmLevofloxacin undergoes limited metabolism
  • Half life7 h; may be prolonged in renal impairment.
  • ExcretionExcreted mainly as the unchanged drug in urine (80 to 85%) and faeces (2%) within 24 h. The major urinary metabolites are desmethyllevofloxacin and levofloxacin N-oxide, each accounting for only 2% of a dose.
  • Urinary Excretion61~87
  • Clerance2.52 ml/min/kg
  • ToxicitySide effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face
  • LD50 (rat)N/A
  • LD50 (mouse)N/A